| Literature DB >> 28378518 |
Mariame Selma Kane1, Jennifer Alban1, Valérie Desquiret-Dumas1,2, Naïg Gueguen1,2, Layal Ishak3, Marc Ferre1, Patrizia Amati-Bonneau1,2, Vincent Procaccio1,2, Dominique Bonneau1,2, Guy Lenaers1, Pascal Reynier1,2, Arnaud Chevrollier1.
Abstract
Optic Atrophy 1 (OPA1) gene mutations cause diseases ranging from isolated dominant optic atrophy (DOA) to various multisystemic disorders. OPA1, a large GTPase belonging to the dynamin family, is involved in mitochondrial network dynamics. The majority of OPA1 mutations encodes truncated forms of the protein and causes DOA through haploinsufficiency, whereas missense OPA1 mutations are predicted to cause disease through deleterious dominant-negative mechanisms. We used 3D imaging and biochemical analysis to explore autophagy and mitophagy in fibroblasts from seven patients harbouring OPA1 mutations. We report new genotype-phenotype correlations between various types of OPA1 mutation and mitophagy. Fibroblasts bearing dominant-negative OPA1 mutations showed increased autophagy and mitophagy in response to uncoupled oxidative phosphorylation. In contrast, OPA1 haploinsufficiency was correlated with a substantial reduction in mitochondrial turnover and autophagy, unless subjected to experimental mitochondrial injury. Our results indicate distinct alterations of mitochondrial physiology and turnover in cells with OPA1 mutations, suggesting that the level and profile of OPA1 may regulate the rate of mitophagy.Entities:
Keywords: OPA1; mitochondria; mitophagy; optic atrophy
Mesh:
Substances:
Year: 2017 PMID: 28378518 PMCID: PMC5618673 DOI: 10.1111/jcmm.13149
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Clinical and molecular description of patients with OPA1 mutations
| Patients (Gender, Age) | Age of onsetOpticAtrophy | Ataxia | Neuropathy | Digestive symptoms | Others | Mutations in OPA1 | Exon/Domain | PROVEAN | Polyphen2 | Sift | MutationTaster | FATHMM | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 (M, 42 years) | 3 years | + | − | − | − | p.Ser545Arg | Exon 17 (Dynamin) c.1635 C>G | −4.585 | 0.991 probably damaging | 0 DAMAGING | 110 disease causing | −3.59 DAMAGING | 7 |
| Patient 2 (M, 49 years) | 5 years | + | − | − | − | p.Ser545Arg | Exon 17 (Dynamin) c.1635 C>G | −4.585 | 0.991 probably damaging | 0 DAMAGING | 110 disease causing | −3.59 DAMAGING | 7 |
| Patient 3 (F, 30 years) | 6 years | − | − | − | Deafness | p.Arg445His | Exon 14 (GTPase) c.1334 G>A | −4.701 | 0.966 probably damaging | 0 DAMAGING | 29 disease causing | −4.21 DAMAGING | 6 |
| Patient 4 (M, 14 years) | 18 months | + | + peripheral neuropathy | + | Cerebellar Atrophy | p.Ile382Met | Exon 12 (GTPase) c.1146 A>G | −2.820 | 0.999 probably damaging | 0 DAMAGING | 10 disease causing | −4.44 DAMAGING | 8 |
| p.Arg824* | Exon 24 (Dynamin) c.2470 C>T |
| Truncation | Truncation | 6 disease causing | Truncation | |||||||
| Patient 5 (F, 4 years) | 14 months | + | + peripheral neuropathy | + | − | p.Ile382Met | Exon 12 (GTPase) c.1146 A>G | −2.820 | 0.999 probably damaging | 0 DAMAGING | 10 disease causing | −4.44 DAMAGING | 8 |
| p.Arg557* | Exon 17 (GTPase) c.1669 C>T |
| Truncation | Truncation | 6 disease causing | Truncation | |||||||
| Patient 6 (M, 15 years) | 36 months | + | + | − | Vermian Atrophy | p.Ile382Met | Exon 12 (GTPase) c.1146 A>G | −2.820 | 0.999 probably damaging | 0 DAMAGING | 10 disease causing | −4.44 DAMAGING | 8 |
| p.Glu487Lys | Exon 15 (GTPase) c.1459 G>A | −2.488 | 0.411 benign | 0.03 DAMAGING | 56 disease causing | −3.65 DAMAGING | |||||||
| Patient 7 (M, 16 years) | 12 months | + | + | − | Epilepsy | p.Ile382Met | Exon 12 (GTPase) c.1146 A>G | −2.820 | 0.999 probably damaging | 0 DAMAGING | 10 disease causing | −4.44 DAMAGING | − |
M, male; F, female. * : Stop.
Figure 1Immunoblot analysis of OPA1 expression in mutant fibroblasts and controls. The protein extracts were obtained from primary cell cultures. Cells were directly quenched with the same buffer as used for cell lysis (see Materials and methods) at 4°C to avoid cleavage of long‐OPA1 into short‐OPA1 isoforms. (A) Immunoblot bands of OPA1 protein. (B) Densito‐metrical analysis of the protein bands shown in A); the figure shows ratios of densities of the protein band to densities of the corresponding tubulin alpha band (TUBA) bands. (C) The figure shows ratios of the long (l‐OPA1) to the short (s‐OPA1) OPA1 isoforms. Data obtained from six independent experiments were analysed. P1‐P7: patients; CTL: controls.
Figure 2Morphology of mitochondrial network and bioenergetics in control and mutated fibroblasts. Cell volumes and shapes were standardized using micropatterned coverslips. Mitochondrial lengths were assessed and colour‐coded (e.g. the red colour represents mitochondria >20 μm). (A) Fibroblasts were incubated in 2/3 Dulbecco's modified Eagle medium and 1/3 Amniomax for 48 hrs, and then loaded with MitoTracker Red as described in Materials and methods. Representatives of 5–10 similar images are shown for each cell line. Scale bar = 10 μm. (B) Bar graphs show the distribution of the mitochondrial population in three different categories on the basis of mitochondrial morphology: ‘filamentous’, mitochondria >20 μm; ‘intermediate’, mitochondria 5–20 μm; and ‘fragmented’, mitochondria <5 μm. (C) Bar graphs show mitochondrial volume quantified as described in Materials and methods. Data were obtained from three independent experiments. (D) Mitochondrial oxidative phosphorylation was analysed on control (CTL) and mutated fibroblasts. Oxygen consumption was measured under basal conditions (Basal respiration graph), in the presence of oligomycin (4 μg/ml) (oligomycin‐insensitive respiration graph), and in the presence of FCCP (4 mM). The respiratory control ratio (RCR graph) was calculated as the ratio of the FCCP‐uncoupled to the oligomycin‐insensitive respiration. Respiration coupled to ATP production (RCRp graph) was calculated as the ratio of the difference between the rates of basal and oligomycin‐insensitive respiration to the uncoupled FCCP respiration. Respiratory reserve capacity was calculated as the ratio of basal respiration to the FCCP‐uncoupled respiration (R/FCCP graph). Data obtained from six independent experiments were analysed. P1‐P7: patients; CTL: controls.
Figure 3Immunoblot analysis of autophagic response proteins in mutated fibroblasts and controls. Levels of autophagy levels were assessed by quantitative analysis of autophagy markers LC3II and P62 in total cell lysates from cells incubated under normal conditions (DMSO) or pre‐treated with either 60 μM chloroquine (4 hrs) or with 10 μM CCCP (24 hrs) using Western Blot analysis. (A–C) The results, represented as LC3II conversion (LC3I/total LC3I+II) and P62, show ratios of protein band densities to the densities of the respective tubulin alpha bands (TUBA) (See Fig. S4). To modulate and test efficiency in these cell lines, control and mutated fibroblasts were incubated in presence of either DMSO (A), a mitochondrial uncoupler CCCP (B), or the autophagy inhibitor chloroquine (C). Data obtained from five independent experiments were analysed. P1‐P7: patients; CTL: controls.
Figure 4Mitophagy in control and mutated fibroblasts. Before experiments, cells were loaded with Lyso‐ID (green) and MitoTracker Red (red) to visualize lysosomes and mitochondria, respectively. (A) The degree of the signal of lysosomes with mitochondria (merge) was calculated via cell live imaging microscopy using a Leica Widefield microscope (for details see Materials and methods). Scale bar = 10 μm. (B–C) The number of lysosomes and mitophagic events were quantified from image acquisitions (For details see Materials and methods). (C) Zoomed regions (insets) from the fluorescent merge images (zoomed from the original picture) illustrate the colocalization of lysosomes (green signal) and mitochondria (red signal), appearing as yellow areas indicative of mitophagy (blue box). The graphs are representative of 30 randomly selected cells from at least 3 independent experiments performed in duplicate. P1‐P7: patients; CTL: controls.
Figure 5Mitophagy regulation in DOA+. DOA, dominant optic atrophy; DN, Dominant Negative; HI, HaploInsufficient; AV, Autophagic vesicle.